Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MYLAN INC. et al v. SMITHKLINE BEECHAM CORPORATION et al
Case Number:
3:10-cv-04809
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 13, 2015
Top IP Awards Of 2014 — And The Firms That Won Them
There were eight intellectual property awards in 2014 that exceeded $100 million, all of them in patent cases, but attorneys say that many of those substantial sums are at risk of being reduced on appeal since the Federal Circuit has heightened its scrutiny of damages awards.
-
January 22, 2015
Mylan Wrings Another $13.7M From GSK In Generic Paxil Row
A New Jersey federal judge on Thursday granted Mylan Inc. supplemental damages of $13.7 million in the generic-drug maker's feud with GlaxoSmithKline PLC over the sale of generic versions of GSK's Paxil by Apotex Inc., bringing the total damages awarded to Mylan to about $120.6 million.
-
August 15, 2014
GSK Appeals Mylan Trial Victory Over Generic Paxil Deal
GlaxoSmithKline PLC has asked the Third Circuit to review a New Jersey federal jury's $106.7 million judgment against the pharmaceutical giant for allowing Apotex Inc. to sell generic versions of Paxil despite a previous license agreement with Mylan Inc., according to a Friday filing.
-
July 16, 2014
Mylan Scores Block On GSK's Generic Paxil Deal
A New Jersey federal judge on Tuesday blocked GlaxoSmithKline PLC from allowing Apotex Inc. to sell generic versions of GSK's antidepressant Paxil under an antitrust settlement, saying a jury had correctly concluded that GSK had breached a previous licensing agreement with Mylan Inc.
-
May 19, 2014
Mylan Can't Use Generic Paxil Case Docs For New Suit
A New Jersey federal judge ruled Monday that Mylan Inc. can't use documents produced during its litigation against GlaxoSmithKline LLC — which allegedly breached a contract by allowing Apotex Inc. to sell generic versions of GSK's antidepressant Paxil as part of an antitrust settlement — to initiate a new lawsuit.
-
April 22, 2014
GSK Slams Mylan's Bid For $3.1M Interest In Paxil Row
GlaxoSmithKline LLC on Monday slammed Mylan Inc.'s bid for $3.1 million in prejudgment interest stemming from the $106.7 million verdict Mylan won after a jury found that GSK breached an exclusive licensing contract arising from an antitrust settlement, saying in New Jersey federal court that the company overstated the amount.
-
March 26, 2014
GSK Handed $106M Verdict For Paxil Generic Contract Breach
A New Jersey federal jury on Tuesday slapped GlaxoSmithKline LLC with a $106.7 million verdict for allegedly breaching an exclusive contract with Mylan Inc. by allowing Apotex Inc. to sell generic versions of its antidepressant Paxil as part of an antitrust settlement.
-
November 02, 2010
Mylan Drops Appeal In Generic Paxil Contract Fight
Mylan Inc. has dropped its nascent appeal of a judge's refusal to enjoin Apotex Corp. from making a copycat version of Paxil CR and entered a discovery plan to litigate its claim that a previous agreement with GlaxoSmithKline PLC gives it the exclusive right to sell a generic form of the antidepressant.